Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
October 01, 2026
October 01, 2026
BOSTON, Massachusetts, Oct. 1 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
*
Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that i . . .
* * *
Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
*
Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that i . . .